Off-label biologic use raises cost and safety concerns – Rheumatology Update
Off-label biologic use raises cost and safety concernsRheumatology UpdateThe study of Australian public hospitals over a six-month period found the monoclonal antibody rituximab was prescribed 364 times for 63 conditions that were not approved under th…